Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin
administration on the disposition of fexofenadine. Clin Pharmacol Ther (St. Louis,
MO, United States) 2001;69:114–121.
Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on
tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999;39:91–96.
Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann
Pharmacother 1999;33:680–682.
Hedman A, Angelin B, Arvidsson A, Dahlqvist R, Nilsson B. Interactions in the renal
biliary elimination of digoxin: stereoselective difference between quinine and
quinidine. Clin Pharmacol Ther (St. Louis, MO. United States) 1990;47:20–26.
Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B, Olsson M,
Schenck-Gustafsson K. Digoxin–verapamil interaction: reduction of biliary but not
renal digoxin clearance in humans. Clin Pharmacol Ther 1991;49:256–262.
Hindmarch I. CNS effects of antihistamines: is there a third generation of non-sedative
drugs? Clin Exp Allergy Rev 2002;2:26–31.
Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and
OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol
Exp Ther 2004;311:139–146.
Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement
of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol
2005;68:800–807.
Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir
and cidofovir is induced by the expression of human renal organic anion transporter
- J Am Soc Nephrol 2000;11:383–393.
Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and
disease. Clin Pharmacol Ther 2005;78:260–277.
Hoffman J. Murine erythroleukemia cells resistant to periodate-oxidized adenosine
have lowered levels of nucleoside transporter. Adv Exp Med Biol 1991;309A:
443–446.
Hoffmaster KA, Turncliff RZ, LeCluyse EL, Kim RB, Meier PJ, Brouwer KLR.
P-glycoprotein expression, localization, and function in sandwich-cultured primary
rat and human hepatocytes: relevance to the hepatobiliary disposition of a model
opioid peptide. Pharm Res 2004a;21:1294–1302.
Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KLR. Hepatobiliary
disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin
(DPDPE): pharmacokinetic consequences of the interplay between multiple
transport systems. J Pharmacol Exp Ther 2004b;311:1203–1210.
Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular
secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther
1993;266:1620–1625.
Horikawa M, Kato Y, Tyson CA, Sugiyama Y. The potential for an interaction
between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate
inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab
Pharmacokinet 2002;17:23–33.
Huang M-J, Kua K-E, Teng H-C, Tang K-S, Weng H-W, Huang C-S. Risk factors for
severe hyperbilirubinemia in neonates. Pediatr Res 2004;56:682–689.
190 DRUG TRANSPORTERS IN DRUG DISPOSITION, DRUG INTERACTIONS